Juan Jesús Carrero

Juan Jesús Carrero

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Juan Jesús Carrero

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Journal of Renal Nutrition
Verified
Journal Article
Open access
PDF file
JCJuan Jesús Carrero
Juan Jesús Carrero
PSPeter Stenvinkel
Peter Stenvinkel
LCLilian Cuppari
Lilian Cuppari
TITalat Alp Ikizler
Talat Alp Ikizler
Kamyar Kalantar-ZadehKamyar Kalantar-Zadeh
Kamyar Kalantar-Zadeh
HFHarold A. Franch
Harold A. Franch
Protein-energy wasting (PEW), a term proposed by the International Society of Renal Nutrition and Metabolism (ISRNM), refers to the multiple nutritional and catabolic alterations that occur in chronic kidney disease (CKD) and associate with morbidity and mortality. To increase awareness, identify research needs, and provide the basis for future work to understand therapies and consequences of PEW, ISRNM provides this consensus statement of current knowledge on the etiology of PEW syndrome in CKD. Although insufficient food intake (true undernutrition) due to poor appetite and dietary restrictions contribute, other highly prevalent factors are required for the full syndrome to develop. These include uremia-induced alterations such as increased energy expenditure, persistent inflammation, acidosis, and multiple endocrine disorders that render a state of hypermetabolism leading to excess catabolism of muscle and fat. In addition, comorbid conditions associated with CKD, poor physical activity, frailty, and the dialysis procedure per se further contribute to PEW.

20 March 2024 in Kidney International
Verified
Journal Article
Open access
ALAdeera Levin
Adeera Levin
SASofia Ahmed
Sofia Ahmed
JCJuan Jesus Carrero
Juan Jesus Carrero
BFBethany Foster
Bethany Foster
AFAnna Francis
Anna Francis
PSPaul Stevens
Paul Stevens
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) updates the KDIGO 2012 guideline and has been developed with patient partners, clinicians, and researchers around the world, using robust methodology. This update, based on a substantially broader base of evidence than has previously been available, reflects an exciting time in nephrology. New therapies and strategies have been tested in large and diverse populations that help to inform care; however, this guideline is not intended for people receiving dialysis nor those who have a kidney transplant. The document is sensitive to international considerations, CKD across the lifespan, and discusses special considerations in implementation. The scope includes chapters dedicated to the evaluation and risk assessment of people with CKD, management to delay CKD progression and its complications, medication management and drug stewardship in CKD, and optimal models of CKD care. Treatment approaches and actionable guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence and the strength of recommendations which followed the "Grading of Recommendations Assessment, Development, and Evaluation" (GRADE) approach. The limitations of the evidence are discussed. The guideline also provides practice points, which serve to direct clinical care or activities for which a systematic review was not conducted, and it includes useful infographics and describes an important research agenda for the future. It targets a broad audience of people with CKD and their healthcare, while being mindful of implications for policy and payment.

1 October 2014 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
NINaohito Isoyama
Naohito Isoyama
AQAbdul Rashid Qureshi
Abdul Rashid Qureshi
CACarla Maria Avesani
Carla Maria Avesani
BLBengt Lindholm
Bengt Lindholm
PBPeter Bàràny
Peter Bàràny
JCJuan Jesús Carrero
Juan Jesús Carrero
Background and objectives Reduced muscle mass and strength are prevalent conditions in dialysis patients. However, muscle strength and muscle mass are not congruent; muscle strength can diminish even though muscle mass is maintained or increased. This study addresses phenotype and mortality associations of these muscle dysfunction entities alone or in combination (i.e., concurrent loss of muscle mass and strength/mobility, here defined as sarcopenia). Design, setting, participants, & measurements This study included 330 incident dialysis patients (203 men, mean age 53±13 years, and mean GFR 7±2 ml/min per 1.73 m2) recruited between 1994 and 2010 and followed prospectively for up to 5 years. Low muscle mass (by dual-energy x-ray absorptiometry appendicular mass index) and low muscle strength (by handgrip) were defined against young reference populations according to the European Working Group on Sarcopenia in Older People. Results Whereas 20% of patients had sarcopenia, low muscle mass and low muscle strength alone were observed in a further 24% and 15% of patients, respectively. Old age, comorbidities, protein-energy wasting, physical inactivity, low albumin, and inflammation associated with low muscle strength, but not with low muscle mass (multivariate ANOVA interactions). During follow-up, 95 patients (29%) died and both conditions associated with mortality as separate entities. When combined, individuals with low muscle mass alone were not at increased risk of mortality (adjusted hazard ratio [HR], 1.23; 95% confidence interval [95% CI], 0.56 to 2.67). Individuals with low muscle strength were at increased risk, irrespective of their muscle stores being appropriate (HR, 1.98; 95% CI, 1.01 to 3.87) or low (HR, 1.93; 95% CI, 1.01 to 3.71). Conclusions Low muscle strength was more strongly associated with aging, protein-energy wasting, physical inactivity, inflammation, and mortality than low muscle mass. Assessment of muscle functionality may provide additional diagnostic and prognostic information to muscle-mass evaluation.

1 March 2008 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
PSPeter Stenvinkel
Peter Stenvinkel
JCJuan Jesu[Combining Acute Accent]S Carrero
Juan Jesu[Combining Acute Accent]S Carrero
JAJonas Axelsson
Jonas Axelsson
BLBengt Lindholm
Bengt Lindholm
ODOlof Heimbu[Combining Diaeresis]Rger
Olof Heimbu[Combining Diaeresis]Rger
ZMZiad Massy
Ziad Massy
Premature cardiovascular disease (CVD), including stroke, peripheral vascular disease, sudden death, coronary artery disease, and congestive heart failure, is a notorious problem in patients with chronic kidney disease (CKD). Because the presence of CVD is independently associated with kidney function decline, it appears that the relationship between CKD and CVD is reciprocal or bidirectional, and that it is this association that leads to the vicious circle contributing to premature death. As randomized, placebo-controlled trials have so far been disappointing and unable to show a survival benefit of various treatment strategies, such a lipid-lowering, increased dialysis dose and normalization of hemoglobin, the risk factor profile seems to be different in CKD compared with the general population. Indeed, seemingly paradoxical associations between traditional risk factors and cardiovascular outcome in patients with advanced CKD have complicated our efforts to identify the real cardiovascular culprits. This review focuses on the many new pieces that need to be fit into the complicated puzzle of uremic vascular disease, including persistent inflammation, endothelial dysfunction, oxidative stress, and vascular ossification. Each of these is not only highly prevalent in CKD but also more strongly linked to CVD in these patients than in the general population. However, a causal relationship between these new markers and CVD in CKD patients remains to be established. Finally, two novel disciplines, proteomics and epigenetics, will be discussed, because these tools may be helpful in the understanding of the discussed vascular risk factors.

1 November 2018 in Journal of Renal Nutrition
Verified
Journal Article
Closed access
PDF file
JCJuan J. Carrero
Juan J. Carrero
FTFridtjof Thomas
Fridtjof Thomas
KNKristóf Nagy
Kristóf Nagy
FAFatiu Arogundade
Fatiu Arogundade
CACarla M. Avesani
Carla M. Avesani
CKCsaba P. Kovesdy
Csaba P. Kovesdy

31 December 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
JKJaimon T Kelly
Jaimon T Kelly
GSGuobin Su
Guobin Su
LZLa Zhang
La Zhang
XQXindong Qin
Xindong Qin
SMSkye Marshall
Skye Marshall
JCJuan-Jesus Carrero
Juan-Jesus Carrero
Significance Statement: Although CKD incidence is increasing, no evidence-based lifestyle recommendations for CKD primary prevention apparently exist. To evaluate evidence associating modifiable lifestyle factors and incidence of CKD, the authors undertook a systematic review and meta-analysis. Their analysis, which included 104 observational studies of 2,755,719 participants, demonstrated consistency of evidence for a number of measures associated with preventing CKD onset, including increasing dietary intake of vegetables and potassium (21% reduced odds and 22% reduced odds, respectively), increasing physical activity levels (18% reduced odds), moderating alcohol consumption (15% reduced risk), lowering sodium intake (21% increased odds), and stopping tobacco smoking (18% increased risk). In the absence of clinical trial evidence, these findings can help inform public health recommendations and patient-centered discussions in clinical practice about lifestyle measures to prevent CKD. Background: Despite increasing incidence of CKD, no evidence-based lifestyle recommendations for CKD primary prevention apparently exist. Methods: To evaluate the consistency of evidence associating modifiable lifestyle factors and CKD incidence, we searched MEDLINE, Embase, CINAHL, and references from eligible studies from database inception through June 2019. We included cohort studies of adults without CKD at baseline that reported lifestyle exposures (diet, physical activity, alcohol consumption, and tobacco smoking). The primary outcome was incident CKD (eGFR<60 ml/min per 1.73 m2). Secondary outcomes included other CKD surrogate measures (RRT, GFR decline, and albuminuria). Results: We identified 104 studies of 2,755,719 participants with generally a low risk of bias. Higher dietary potassium intake associated with significantly decreased odds of CKD (odds ratio [OR], 0.78; 95% confidence interval [95% CI], 0.65 to 0.94), as did higher vegetable intake (OR, 0.79; 95% CI, 0.70 to 0.90); higher salt intake associated with significantly increased odds of CKD (OR, 1.21; 95% CI, 1.06 to 1.38). Being physically active versus sedentary associated with lower odds of CKD (OR, 0.82; 95% CI, 0.69 to 0.98). Current and former smokers had significantly increased odds of CKD compared with never smokers (OR, 1.18; 95% CI, 1.10 to 1.27). Compared with no consumption, moderate consumption of alcohol associated with reduced risk of CKD (relative risk, 0.86; 95% CI, 0.79 to 0.93). These associations were consistent, but evidence was predominantly of low to very low certainty. Results for secondary outcomes were consistent with the primary finding. Conclusions: These findings identify modifiable lifestyle factors that consistently predict the incidence of CKD in the community and may inform both public health recommendations and clinical practice.